Roswell doctors develop new medicine that could ease treatment for aggressive form of brain cancer

News

A team of two doctors, at Roswell Park Cancer Institute, have developed a new type of Immunotherapy to help patients with Glioblastoma, a type of brain cancer.

The treatment is called SurVaxM. It helps a person’s immune system attack tumor cells. The results form the first phase of testing showed those newly diagnosed with Glioblastoma had a longer survival time when treated.

This vaccine treatment was designed as a less toxic alternative to traditional cancer treatments

“It works similar to how you think a flu vaccine works,” said Michael Ciesielski, Chief executive officer of MimiVax. MimiVax is a Roswell Park spinoff company spearheading the clinical trial. “It’s a shot in the arm and it stimulates your own immune system to hunt down and attack tumor cells using t-cells and antibodies, and parts of your own immune system to help identify those tumor cells.”

MimiVax received $10 million from Shanghai Fosun Pharmaceutical Co. to continue with the next phase of its trails.

Copyright 2019 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories

Don't Miss